KalVista Pharmaceuticals (NASDAQ: KALV), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced that it has closed on upsized underwritten public offering. The offering consisted of 6,181,250 shares of its common stock; an additional 806,250 shares were included in the offering, which were sold in accordance with the full exercise of the over-allotment option granted to underwriters. The shares were sold for $36 per share, with the offering ultimately resulting in an estimated $222.5 million in gross proceeds for KalVista. According to the announcement, Roth Capital Partners acted as co-manager for the offering.
To view the full press release, visit https://nnw.fm/GMtRr
About KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (“HAE”) and diabetic macular edema (“DME”). KalVista is developing KVD900 (“KVD900”) as an oral on-demand therapy for acute HAE attacks, which completed a phase 2 efficacy trial in February 2021, demonstrating statistical and clinical significance across all endpoints. KVD824 is in development for prophylactic treatment of HAE with an expected IND filing for a Phase 2 clinical trial in the first quarter of 2021. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001 (KVD001”), has completed a phase 2 clinical trial. For more information, please visit www://ir.KalVista.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork